Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BUCET vs TENCON
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Bucet is a combination of bucetin and acetaminophen. Bucetin is a para-aminophenol derivative with analgesic and antipyretic effects, possibly through inhibition of cyclooxygenase in the central nervous system. Acetaminophen inhibits COX enzymes in the brain, reducing prostaglandin synthesis and fever.
Tencon is a combination product containing butalbital, acetaminophen, and caffeine. Butalbital is a barbiturate that enhances GABA activity at GABA-A receptors, producing sedation and anxiolysis. Acetaminophen inhibits cyclooxygenase (COX) enzymes centrally, reducing prostaglandin synthesis and pain perception. Caffeine is a non-selective adenosine receptor antagonist, promoting alertness and vasoconstriction.
Management of mild to moderate pain,Reduction of fever
Tension headache,Migraine headache (off-label)
Oral: 25-50 mg every 4-6 hours as needed for pain; maximum 200 mg/day.
5 mg orally once daily, increased to 10 mg if needed after 2 weeks; maximum 20 mg daily.
2-4 hours (terminal); prolonged in renal impairment
Terminal half-life 2-4 hours; prolonged to 6-15 hours in renal impairment (Cr Cl <30 m L/min).
Bucetin: Hepatic metabolism via hydroxylation and glucuronidation. Acetaminophen: Hepatic metabolism via glucuronidation, sulfation, and CYP2E1-mediated oxidation to NAPQI.
Butalbital is metabolized primarily by cytochrome P450 (CYP) enzymes. Acetaminophen is metabolized mainly in the liver via glucuronidation, sulfation, and oxidation (CYP2E1, CYP1A2, CYP3A4) to reactive metabolites that are conjugated with glutathione. Caffeine is metabolized by CYP1A2.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
Primarily renal excretion (66-74% unchanged); biliary/fecal excretion (26-34%).
~85% bound to albumin
25-30% bound to albumin.
0.3-0.5 L/kg; distributes primarily into extracellular fluid
0.3-0.5 L/kg; indicates distribution into total body water.
Oral: 75-90%
Oral: 85-90% (extensive first-pass metabolism reduces bioavailability to 60-70% for parent drug, but active metabolite contributes).
GFR 10-50 m L/min: 50% dose reduction; GFR <10 m L/min: avoid use.
GFR >30 m L/min: no adjustment; GFR 15-30 m L/min: 5 mg once daily; GFR <15 m L/min: contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: 50% dose reduction; Child-Pugh C: avoid use.
Child-Pugh A: 5 mg once daily; Child-Pugh B: 2.5 mg once daily; Child-Pugh C: contraindicated.
Children 6-12 years: 5 mg/kg/dose every 6 hours as needed; maximum 20 mg/kg/day.
0.1 mg/kg orally once daily, maximum 5 mg; titrate after 2 weeks; maximum 10 mg.
Start at lowest effective dose (12.5 mg every 6 hours); maximum 150 mg/day due to increased fall risk and renal impairment.
Initiate at 2.5 mg orally once daily; increase cautiously to maximum 10 mg daily.
No FDA black box warnings for bucet. Acetaminophen component: Risk of severe liver injury at high doses or with alcohol use.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4000 mg per day, and often involve more than one acetaminophen-containing product.
Hepatotoxicity risk with acetaminophen overdose,Avoid alcohol use,Hypersensitivity reactions,Skin reactions (Stevens-Johnson syndrome)
Hepatotoxicity with acetaminophen overdose; risk of dependence and withdrawal with butalbital (barbiturate); may impair ability to drive or operate machinery; avoid concurrent use with other acetaminophen-containing products; caution in patients with liver disease, renal impairment, or history of substance abuse.
Severe hepatic impairment,Hypersensitivity to bucetin or acetaminophen
Known hypersensitivity to barbiturates, acetaminophen, or caffeine; porphyria; severe hepatic impairment; acute or chronic pain in patients with active alcoholism; concomitant use with other CNS depressants (relative contraindication).
No known food interactions. Avoid alcohol as it may increase risk of side effects like dizziness.
Avoid alcohol consumption due to increased risk of acetaminophen hepatotoxicity and additive central nervous system depression. Limit caffeine-containing foods and beverages (coffee, tea, cola, chocolate) to avoid excessive stimulant effects and potential caffeine toxicity.
FDA Pregnancy Category D. First trimester: Increased risk of cardiac malformations and neural tube defects. Second and third trimesters: Risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment.
FDA Pregnancy Category B. No evidence of risk in first trimester based on animal studies; insufficient human data for second and third trimesters. Recommend use only if clearly needed.
Contraindicated. Excreted in human milk; M/P ratio not established. Potential for serious adverse effects in nursing infant.
Unknown if excreted in human milk. M/P ratio not determined. Use with caution in nursing mothers.
Avoid use during pregnancy. If unavoidable, reduce dose by 50% due to increased clearance and altered protein binding.
No dose adjustment recommended for pregnancy; increased renal clearance in late pregnancy may require dose titration based on therapeutic drug monitoring.
Bucet (bupivacaine hydrochloride and epinephrine) is used for local anesthesia. Epinephrine prolongs anesthetic effect and reduces systemic absorption. Avoid in patients with severe hypertension, hyperthyroidism, or concurrent MAO inhibitors. Monitor for CNS and cardiac toxicity, especially with high doses. Epinephrine concentration is 1:200,000; check for allergy to sulfites (antioxidant).
Tencon is a combination analgesic containing acetaminophen, butalbital, and caffeine. It is indicated for tension headaches. Butalbital is a barbiturate with abuse potential; limit duration of use to avoid dependence. Acetaminophen hepatotoxicity risk increases with doses >4 g/day or in patients with hepatic impairment. Caffeine may exacerbate anxiety or insomnia. Monitor for signs of barbiturate withdrawal (anxiety, tremor, seizures) if discontinued abruptly after prolonged use.
Do not drive or operate machinery until numbness subsides.,Avoid touching or scratching the numb area to prevent injury.,Report any signs of allergic reaction (rash, swelling, difficulty breathing) or intravenous injection symptoms (rapid heart rate, anxiety, headache).,The numbness will wear off over several hours depending on the dose and site.
Take exactly as prescribed; do not exceed recommended dose.,Avoid alcohol while taking this medication due to increased liver damage risk.,Do not take with other products containing acetaminophen (e.g., Tylenol, cold medicines).,This drug can be habit-forming; do not use longer than directed.,May cause drowsiness or dizziness; avoid driving or operating heavy machinery until you know how it affects you.,Limit caffeine intake from other sources (coffee, tea, soda) to prevent overstimulation.,If you miss a dose, take it as soon as you remember; do not double the next dose.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BUCET vs TENCON, answered by our medical review team.
BUCET is a Barbiturate Combination Analgesic that works by Bucet is a combination of bucetin and acetaminophen. Bucetin is a para-aminophenol derivative with analgesic and antipyretic effects, possibly through inhibition of cyclooxygenase in the central nervous system. Acetaminophen inhibits COX enzymes in the brain, reducing prostaglandin synthesis and fever.. TENCON is a Barbiturate combination analgesic that works by Tencon is a combination product containing butalbital, acetaminophen, and caffeine. Butalbital is a barbiturate that enhances GABA activity at GABA-A receptors, producing sedation and anxiolysis. Acetaminophen inhibits cyclooxygenase (COX) enzymes centrally, reducing prostaglandin synthesis and pain perception. Caffeine is a non-selective adenosine receptor antagonist, promoting alertness and vasoconstriction.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BUCET and TENCON depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BUCET is: Oral: 25-50 mg every 4-6 hours as needed for pain; maximum 200 mg/day.. The standard adult dose of TENCON is: 5 mg orally once daily, increased to 10 mg if needed after 2 weeks; maximum 20 mg daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BUCET and TENCON in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BUCET is classified as Category C. FDA Pregnancy Category D. First trimester: Increased risk of cardiac malformations and neural tube defects. Second and third trimesters: Risk of premature closure of ductus arterio. TENCON is classified as Category C. FDA Pregnancy Category B. No evidence of risk in first trimester based on animal studies; insufficient human data for second and third trimesters. Recommend use only if clearly nee. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.